Close Menu

Gilead Sciences

Not Convened

Science reports the US Food and Drug Administration did not consult an outside panel in its approval of remdesivir as a COVID-19 treatment.

Early trials give conflicting results on remdesivir to treat COVID-19, though a large trial suggests it shortens disease length, Nature News reports.

In PLOS this week: genomic analysis of multidrug-resistant Mycobacterium tuberculosis strains from Colombia, inflammatory response signatures in cancer, and more.

Second Genome will use its Microbiome Analytics platform to identify novel biomarkers linked to clinical responses to Gilead's investigational medicines.

The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.

Slow Adoption

Reuters reports that slow adoption of CAR-T therapies might be tied to their high prices.

The agreement is part of Biocartis' long term plans to expand its presence in the oncology field by building a menu of tests for immunotherapies.

Miles to Go

Technology Review maps out where new gene therapies for cancer patients are available, noticing an urban-rural divide.

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

Lasker Honorees

The Albert and Mary Lasker Foundation has announced this year's recipients of its prizes honoring basic and clinical research.

Pages

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.